AmpliPhi BioSciences Corp has placed $7 million of convertible preferred stock with a group of life science investors in order to finance the development of therapeutics for infectious diseases including bacterial infections.
Roche and AstraZeneca Plc have entered into a deal to share certain know-how in the area of medicinal chemistry in order to accelerate the discovery of new pharmaceutical compounds. Financial details were not disclosed.
Basilea Pharmaceutica Ltd said its has signed a contract with the US Biomedical Advanced Research and Development Authority (BARDA) to co-develop a monosulfactam antibiotic for multidrug-resistant Gram negative bacteria.
Cardio3 BioSciences SA of Belgium said that its previously announced initial public offering of shares will commence on 21 June and end on 3 July. The indicative price range of the shares is between €16.65 per share and €19.00 per share.
Johnson & Johnson Inc is set to pay up to $1 billion to acquire privately-held Aragon Pharmaceuticals Inc of the US which has a product in Phase 2 development for castration resistant prostate cancer. The upfront payment is $650 million.
Index Ventures is launching a virtual, single-product company that is developing a monoclonal antibody with the potential, it says, to prevent heart attack and stroke without causing bleeding. The antibody targets the clotting enzyme thrombin. The funding was announced on 17 June.
AstraZeneca Plc is to pay up to $1.15 billion to acquire privately-held Pearl Therapeutics Inc of the US which has a Phase 3 product in development for chronic obstructive pulmonary disease, as well as inhaler and formulation technology with potential application in future combination products.
Cardio3 BioSciences SA of Belgium has announced plans to raise new funds through an initial public offering of its shares on the NYSE Euronext exchanges in both Brussels and Paris. The company has a cell therapy for heart repair in Phase 3.
MorphoSys AG has successfully outlicensed its first proprietary antibody, MOR103 for rheumatoid arthritis, to GlaxoSmithKline Plc in a deal potentially valued at €445.5 million. The German company is set to receive an upfront payment of €22.5 million.
Horizon Discovery Ltd has announced the final closing of its Series C funding round with share placements valued at £6.9 million. The total sum raised in the round is £18.2 million which will be used to advance its research tools including cell lines.